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Despite the success of the adenovirus vaccine admin-
istered to US military trainees, acute respiratory disease
(ARD) surveillance still detected breakthrough infections
(respiratory illnesses associated with the adenovirus
serotypes specifically targeted by the vaccine). To explore
the role of adenoviral co-infection (simultaneous infection
by multiple pathogenic adenovirus species) in break-
through disease, we examined specimens from patients
with ARD by using 3 methods to detect multiple adenoviral
species: a DNA microarray, a polymerase chain reaction
(PCR)–enzyme-linked immunosorbent assay, and a multi-
plex PCR assay. Analysis of 52 samples (21 vaccinated, 31
unvaccinated) collected from 1996 to 2000 showed that all
vaccinated samples had co-infections. Most of these co-
infections were community-acquired serotypes of species
B1 and E. Unvaccinated samples primarily contained only
1 species (species E) associated with adult respiratory ill-
ness. This study highlights the rarely reported phenomenon
of adenoviral co-infections in a clinically relevant environ-
ment suitable for the generation of new recombinational
variants. 
A
denoviruses cause an estimated 8% of clinically rele-
vant viral disease globally (1). Human adenoviruses
(HAdVs) are divided into 51 serotypes (HAdV-1–HAdV-
51) on the basis of type-specific antiserum-mediated neu-
tralization of infectivity (determined primarily by the
hexon coat protein and terminal knob portion of the fiber
protein) (2) and into 6 species, also referred to as subgen-
era or subgroups (HAdV-A, B, C, D, E, and F) on the basis
of hemagglutination inhibition and biochemical criteria
(3–5). Species HAdV-B is further classified into sub-
species B1 and B2 (3). In civilian populations, HAdV-B1
serotypes 3, 7, 16, and 21; HAdV-E serotype 4; and 1
member of subspecies HAdV-B2, serotype 14, cause out-
breaks of illness ranging from mild febrile respiratory
infections and conjunctivitis to potentially lethal dissemi-
nated infections in both adults and children (1,6). HAdV-C
serotypes 1, 2, 5, and 6 cause locally endemic upper respi-
ratory infections in infants and children (7,8) and occa-
sional outbreaks in adults. Other HAdV species are usually
not associated with respiratory disease in otherwise
healthy humans.
HAdV seems to have found a particularly destructive
niche in military training camps. HAdV-B1 serotypes 3, 7,
and 21; HAdV-E serotype 4; and HAdV-B2 serotype 14
have caused severe outbreaks of acute respiratory disease
(ARD) among military recruits in training centers (9,10).
Before initiation of an HAdV vaccination program in 1971,
outbreaks occurred regularly, and ≈1 of 6 recruits in affect-
ed camps required hospitalization (1). Systematic vaccina-
tion of recruits against the 2 most common agents of ARD
in the military, HAdV serotypes 4 and 7, decreased HAdV-
specific respiratory illness by 95% to 99% and overall res-
piratory illness rates by 50% to 60% (11–13). Despite this
general efficacy, breakthrough infection (infection of vacci-
nated persons by the vaccine-targeted adenoviral serotypes)
was still regularly reported (14). Production of the vaccine
was suspended in 1996, at which point vaccination became
sporadic until the existing stocks ran out in 1999. ARD
rates quickly returned to prevaccine levels, with HAdV as
the apparent causal agent. As a result, reintroduction of the
vaccine is being actively pursued (15).
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Center population-based febrile respiratory illness surveil-
lance collection from vaccinated (n = 21) and unvaccinat-
ed (n = 31) recruits who reported ARD from 1996 to 2000.
Samples were chosen that had tested positive for serotypes
4 or 7 by culture and serotypic antibody neutralization. The
gene coding for the primary adenoviral antigen, the hexon
coat protein, was sequenced from these isolates. The
sequence data suggested that the detectable serotype 4 and
7 strains apparently responsible for breakthrough infection
were the same as those circulating in unvaccinated military
and civilian populations (16). In this study, we reanalyze
the same set of samples to identify co-infections with mul-
tiple HAdV strains and to address what role co-infections
may play in breakthrough infection. 
Materials and Methods
Sample Collection and Preparation
Samples were collected as throat swabs into viral trans-
port medium from military recruits with ARD at a variety
of training camps as previously described (16). The throat
swab samples were cultured on A549 cells and tested by
using standard serologic methods. Both original swabs and
in vitro tissue culture fluid (ITCF) samples were stored at
–80°C. Samples that initially tested positive for serotypes
4 or 7 by culture and microneutralization were chosen for
analysis and grouped by previous vaccination status. DNA
extracts from ITCF samples were collected and used in
molecular assays. Collection details and symptom defini-
tions were previously reported (16), and sample details are
shown in Tables 1 and 2. Initially, 13 unidentified (blind-
ed) samples were sent by the Naval Health Research
Center to the Naval Research Laboratory personnel for
testing. After the initial 13 samples showed a high rate of
respiratory HAdV co-infection, primarily in vaccinated
persons, an additional 39 samples were tested in an
unblinded fashion.
Microarray-based Genotyping
One microliter of purified DNA extract from each of
the 52 ITCF samples was used as the template in 50-µL
degenerate PCR amplifications targeting portions of the
E1A, hexon, and fiber genes. The primers, degenerate
polymerase chain reaction (PCR) amplification protocol,
probes, and microarray fabrication techniques have been
previously described (18). Once constructed, the spotted
microarrays were blocked with a 3% bovine serum albu-
min–casein solution (BSA-C) for 15 min at room temper-
ature, and the slides were outfitted with MAUIMixer DC
hybridization chambers (BioMicro Systems, Salt Lake
City, UT, USA). Twenty-microliter hybridization reactions
(13.6 µLbiotinylated degenerate PCR amplicons, 2 µL3%
BSA-C, 4 µL2 0 × SSC (0.3 mol/L sodium citrate, 3.0
mol/LNaCl, pH 7.0), and 0.4 µL10% sodium dodecyl sul-
fate [SDS]) were denatured for 3 min at 98°C and imme-
diately applied to the microarrays. Hybridizations were
performed for 2 h at 63°C in a MAUI Hybridization
System (BioMicro Systems). Slides were then washed
twice with 4× SSC-0.2% SDS buffer and 2× SSC buffer,
and hybridization was detected by the sequential addition
of Cy5-conjugated mouse antibiotin immunoglobulin G
(IgG) (Jackson ImmunoResearch, West Grove, PA, USA)
and Cy5-conjugated goat antimouse IgG (Jackson
ImmunoResearch). Images were obtained with a
ScanArray Lite confocal laser scanning system (Perkin-
Elmer, Torrance, CA, USA) at a laser power of 60 to 80
and a photomultiplier tube gain of 60 to 80. The fluores-
cent signal from each microarray element was considered
positive only when its quantified intensity was >3× that of
known internal negative control elements. Each ITCF sam-
ple was subjected to 2 to 5 independent amplification and
hybridization experiments. Hybridization patterns unique
to specific serotypes were determined empirically with
prototype strains (18). Although members of species
HAdV-B1 often produced complex hybridization profiles
(18), these profiles were unique, reproducible, and readily
identifiable in both single infections and co-infections.
Adenovirus Consensus PCR–Enzyme-linked
Immunosorbent Assay
We used a commercially available kit capable of typing
adenoviruses to the species level to confirm the results
obtained with microarray analyses. Briefly, the Adenovirus
Consensus kit (Argene, North Massapequa, NY, USA)
uses a PCR–enzyme-linked immunosorbent assay that
amplifies a fragment from the adenovirus virus-associated
(VA) RNA gene and subsequently detects and types the
amplicon with species-specific biotinylated oligonu-
cleotide probes in a colorimetric microwell format (19).
Results obtained with the kit were interpreted according to
the manufacturer’s adenovirus typing protocol. 
Adenovirus-specific PCR
The species-specific PCR amplification was performed
with previously published primers (20) and a Multiplex
PCR Kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s instructions (with 0.5× Q solution). These
amplifications were performed in 25-µL reaction volumes
at an annealing temperature of 52°C. In general, the PCRs
were performed in an iCycler (Bio-Rad, Hercules, CA,
USA) and analyzed by electrophoresis on 1.5% agarose
gels. Monoplex PCR was performed under identical reac-
tion conditions, except that the same primers were used in
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microneutralization assays were performed as previously
described (21,22). Serotype-specific PCR assays (Tables 1
and 2) were verified as described (20,23–26), with occa-
sional substitutions of polymerase type and annealing tem-
perature adjustments. 
Co-infection Separation
Limiting dilutions of ITCF sample 7151 were plated on
A549 cells and allowed to adsorb for 16 hours, after which
agarose overlays (0.4% agarose in Dulbecco minimal
essential medium, 2% fetal bovine serum, 4 mmol/L glut-
amine) were added to each infected monolayer. Well-sepa-
rated virus plaques were picked 5 days postinfection,
placed into viral transport medium, and tested by PCR for
HAdV-B and HAdV-C. Asecond round of plaque purifica-
tion was performed on several plaque isolates that were
treated with 0.05% Triton-X 100 to potentially disrupt
virus clumps before their dilution and plating. After 6
hours of adsorption, the original inoculum was removed,
and the monolayers were overlayed with agarose solution.
The newly formed plaques were tested as described above.
Results
By using a new 70-mer spotted microarray (18), a
PCR–enzyme-linked immunosorbent assay (19), and a
species-specific multiplex PCR assay (20), we generated
data profiles for each of the 52 tissue culture-amplified
samples; the raw data from 2 of these samples are shown as
representative examples (Figure). The microarray profile of
vaccinated sample 7274 detected HAdV-4 (species E),
HAdV-21 (species B1), HAdV-C, and HAdV-B2 according
to previously validated hybridization patterns (18) (Figure,
panel A). Except for detection of an apparent low-level
HAdV-C co-infectant, the results of the Adenovirus
Consensus kit (HAdV-B1, HAdV-B2, and HAdV-E)
(Figure, panel B), multiplex and monoplex species-specific
PCR (HAdV-B and HAdV-E) (Figure, panel C), and
serotype-specific PCR (HAdV-4, HAdV-21, and HAdV-
B2) (Figure, panel D) confirmed the microarray-based
identification of multiple adenoviral strains in sample 7274. 
In contrast, the microarray profile of unvaccinated sam-
ple 10756 detected a single serotype, HAdV-4 (Figure,
panel E). The microarray-based finding was verified by
results of the Adenovirus Consensus kit (Figure, panel F),
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Figure. Molecular methods used to identify human adenovirus (HAdV) co-infections. A–D) Vaccinated sample 7274. A) Microarray
hybridization profile. White and yellow rectangles indicate low-positive HAdV-C and HAdV-B2 targets, respectively. Spot colors denote
hybridization signal intensity (white > yellow > green > blue). Species and corresponding serotype designations are indicated on the left.
Probe designations (E1, E2 = serotype-specific E1A probes; H1, H2 = serotype-specific hexon probes; F1, F2 = serotype-specific fiber
probes) are indicated above each array. B) Adenovirus Consensus kit optical density values. *, amplification positive. The horizontal line
is the manufacturer's significance threshhold. C) Multiplex species-specific polymerase chain reaction (PCR). m, molecular mass mark-
er. Species designations are to the right of the corresponding band. D) PCR verification with independent serotype or species-specific
primers. E–H) Unvaccinated sample 10756. E) Microarray hybridization profile. F) Adenovirus Consensus kit optical density values.
G) Multiplex species-specific PCR. H) PCR verification with independent serotype-specific primers. multiplex species-specific PCR (Figure, panel G), and
HAdV-4 serotype-specific PCR (Figure, panel H). The
data profiles for all 52 samples assembled and compared in
this manner are shown in Tables 1 and 2. Dual, triple, and
quadruple infections were found in all 21 of the vaccinat-
ed samples and in 14 of the 31 unvaccinated samples test-
ed (Tables 1 and 2). 
Previously vaccinated persons showed a high rate of
co-infection with both species commonly associated with
ARD (HAdV-B1 and HAdV-E), whereas unvaccinated
persons were primarily infected with HAdV-E. Since
HAdV-4 and HAdV-7 are the 2 most common ARD-asso-
ciated serotypes, that they were also the most commonly
paired respiratory pathogenic co-infectants detected in
vaccinated persons is not surprising. When the vaccine
was used, the rates of other respiratory adenoviruses were
much higher than when the vaccine was not used (16).
However, these isolates were chosen for study because
they yielded antigenic signals consistent with either
HAdV-4 or HAdV-7 and were therefore expected to con-
tain at least 1 of these 2 viruses as the highest titer aden-
oviral components (Table 1) (16). 
The ability of the microarray to identify to the serotype
level resulted in the detection of the greatest number of co-
infections, despite its inability to detect members of
species B2 when a co-infecting HAdV-7 was present
(hybridization pattern interference) and members of
species F that were not targeted (Table 3). Microarray-
based identification of multiple ARD-associated serotypes
from diverse HAdV-B1 species (serotypes 3, 7, and 21)
was necessary because co-infections with these serotypes
would not have been indicated or resolved by methods lim-
ited to species-level identification. 
Although most apparent co-infections could be verified
by each of the primary methods tested and by serotype-
specific PCR (e.g., single infections: 10756, 60406, 20142;
co-infections: 1212, 7151, 7274), some could not be veri-
fied (e.g., 60691, CHPPM2). Those co-infectant signals
that could not be verified were usually weak positives. The
strains responsible for these signals appeared to be subor-
dinate co-infectants because the predominant serotype or
species signals generated for the associated samples by the
microarray, Adenovirus Consensus kit, and serotype-spe-
cific PCR were corroborated in every case and matched the
results obtained from the sequencing experiments previ-
ously reported (16). 
The microarray and Adenovirus Consensus kit use
detection and signal amplification techniques that enhance
assay sensitivity and thus render them more sensitive than
traditional PCR/agarose gel visualization techniques, as
shown by the number of triple and quadruple co-infections
detected with these techniques (Table 3). Thus, attempting
to corroborate these methods with the 3 PCR-based meth-
ods used was not completely successful. Nevertheless,
most of the positive results from these tests were verified
by comparing the microarray and Adenovirus Consensus
kit results or by comparison with the results from inde-
pendent methods such as microneutralization, hexon
sequence analysis, serotype-specific PCR that uses primers
not used in the multiplex tests, and PCR amplicon
sequencing (Tables 1, 2, and 4). These results suggest that
these methods can identify and corroborate HAdV co-
infections and that, in general, the HAdV load in ARD
patients is more complex than previously thought.
To determine whether >1 replication-competent
serotype or strain was present in the samples with evidence
of co-infection, we attempted to physically separate the
paired co-infectants in sample 7151 by plaque purification.
Of 92 plaques picked from the initial plate, all tested posi-
tive for HAdV-C by PCR and 12 of 92 also tested positive
for HAdV-B. Several of the plaques that retained both
HAdV-B and HAdV-C signals were replaqued, and PCR
testing of these plaques yielded only HAdV-C isolates.
Further efforts that used a detergent to increase separation
within the original ITCF sample 7151 and applied the
agarose overlay more quickly (6 hours) to prevent inter-
plaque contamination also yielded only HAdV-C plaques
(data not shown).
Discussion
We demonstrate the rarely reported phenomenon of co-
infections with multiple adenoviral species. Two previous
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tions in small numbers (27,28). HAdV-C, although rarely
associated with pharyngitis outbreaks in recruits (10), is
usually seen in children (7,8) and can produce latent infec-
tions that last into young adulthood. This fact, combined
with low incidence of co-infection (27,28), has led to the
assertion that multistrain adenovirus co-infections are not
common (28) or clinically relevant. The results from the
population tested in this study suggest otherwise. Samples
from vaccinated recruits showed a high rate of co-infection
with multiple species of adenovirus associated with adult
ARD (HAdV-E and HAdV-B1).
Many of the identified co-infectants in this study were
species not generally associated with ARD in the military
(HAdV-C, HAdV-B2, and HAdV-F). Although these
species were not likely the cause of ARD observed in these
patients, since they are not believed to cause ARD in adults
and because they have a high potential for latent carriage
(1,7,8,29), their presence sheds new light on the general
complexity of the human adenoviral load. In addition, they
remain viable reservoirs capable of genetic complementa-
tion or recombination with upper respiratory strains.
Recombination can generate new strains with unique
and stable phenotypes. Intraspecies adenovirus recombina-
tion has been demonstrated in laboratory cell-culture co-
infection studies (30–32). These recombination events can
generate viable hybrids with intermediate or unique
immunogenic and tropic properties. Evidence suggests
recombination can generate hybrids in immunocompro-
mised patients (29,33,34), possibly as a result of co-infec-
tion with normally isolated serotypes. Recombination,
particularly intraspecies, seems to play a major role in the
evolution of new, virulent strains of HAdV (1,17,35,36).
The currently dominant pathogenic HAdV in US military
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(16), appears to be a recent recombinant between HAdV-4
and an HAdV-B1 serotype, probably HAdV-7 (37). Given
that these 2 are the most common co-infectants seen in our
sample set, this finding suggests that the observed domi-
nance of co-infections in vaccinated persons may have
contributed to the emergence of the new variant. In gener-
al, the understanding and control of situations that create
or promote co-infection may be important considerations.
The HAdV vaccine, an enteric-coated live-virus tablet
designed to transiently and selectively infect the gastroin-
testinal tract with normal respiratory HAdV strains, con-
tains viable HAdV-4 and HAdV-7. Thus, we cannot
assume whether the detected co-infectants arose from the
vaccine itself or from community acquisition of circulating
strains. Most HAdV-4 strains in this study are not the vac-
cine strain but rather a highly divergent variant that has
recently been dominant in military training centers
(GenBank strain Z-G 95-873). This identity was shown by
sequence analysis of 1,500 bp of the hexon gene from
many primary infectants identified in the same sample set
that was analyzed here (16). The variant HAdV-4 isolates
consistently differ from the vaccine strain by 32 base sub-
stitutions, including 9 coding changes, in this region (16)
(Table 1). Hexon sequence analysis showed that many
HAdV-7 co-infectants are HAdV-7d2. HAdV-7d2 is distin-
guished from the HAdV-7 vaccine strain (HAdV-7a) by a
single coding polymorphism in the hexon sequence, but
this polymorphism (protein L443Q or nucleotide T1328A
in GenBank [16]) is specific to HAdV-7d and HAdV-7d2
and is not found in HAdV-7a, b, c, g, or h or in the vaccine
strain (16,38,39). Three of the other HAdV-7 co-infectants
(1856, 4185, and 7372) were shown to be HAdV-7h by
fiber gene sequencing. The fiber gene of HAdV-7h appears
to have been horizontally transferred from HAdV-3 and
thus is highly diverged from the usual HAdV-7 fiber gene,
as found in the vaccine strain (17). Thus, sequence analy-
ses show that most, if not all, co-infectants are currently
circulating HAdV-4 and HAdV-7 strains that are distinct
from the vaccine strains (16) (Table 1).
Four lines of evidence support the idea that most of the
apparent genetic complexity in the throat swab samples
comes from multiple strains, as opposed to recombinants
with mixed genetic characteristics. The first comes from
the microarray data. The microarray tests for hybridization
of 6 independent probes designed to match serotype-spe-
cific sequences in 3 genes (18). Since different species do
not cross-react among the microarray probes, hybridiza-
tion of genes from 1 species to the identifying probes for 2
species would require redundant presence of 2 different
alleles in all 3 genes. Since both natural recombination in
hosts (17) and artificially encouraged recombination in
cell culture (30,32) strongly favor homologous recombina-
tion and generation of nonredundant hybrid strains, redun-
dant characterization of paired, divergent alleles is incon-
sistent with a single recombinant genome. 
The second line of evidence supporting co-infection
with independent genomes comes from comparisons of
relative co-infectant titers before and after potentially
selective events, such as growth in tissue culture. PCR
amplification of fiber gene sequences using species B- and
E-specific primers was performed on serial dilutions of
vaccinated sample 7274 before and after passage of the
original ITCF through 2 additional cycles of growth in
A549 cells. In this instance, the relative titers of HAdV-4
and HAdV-7, as measured by serial-dilution PCR, changed
by 2 orders of magnitude (data not shown). The rapid drift
in relative concentrations of PCR targets from paired co-
infecting strains strongly suggests that the co-infectants’
genomes are replicating independently and thus likely to
be physically separate entities. 
The third line of evidence supporting co-infectant inde-
pendence comes from whole-genome sequencing efforts.
Several molecular methods indicated that vaccinated sam-
ple 7151 harbored an HAdV-5/HAdV-21 co-infection
(Tables 1 and 2). The genome of the HAdV-5 co-infecting
strain was sequenced and assembled into a contiguous
sequence (GenBank no. AY601635) consistent with a pub-
lished HAdV-5 genome (GenBank accession no.
AY339865) (40), which suggested no recombination of
foreign DNA. However, this effort also generated several
orphan sequences that did not fit into the assembled
sequence and were subsequently identified as genetically
redundant HAdV-21 regions. Further amplification and
sequencing of several genetically distant fragments from
the same sample using HAdV-21-specific primers yielded
≈2 kb of HAdV-21 sequence. On the basis of the entire
genome and partial PCR sequencing analyses, >2 co-
infecting HAdV genomes are contained in sample 7151.
The fourth line of evidence comes from our attempts to
physically separate paired co-infectants by plaque purifi-
cation. Sample 7151, which contained the HAdV-5/HAdV-
21 co-infection, was used initially because it contained
relatively equal titers of both co-infectants. Although most
of the plaques tested contained HAdV-5, some contained
both HAdV-5 and HAdV-21. Although we were unable to
identify plaques that contained only HAdV-21, our results
demonstrate the physical independence of the co-infecting
entities and the functional independence of HAdV-5. Our
results also suggest that either the HAdV-21 co-infectant is
functionally dependent on HAdV-5 or is effectively out-
grown by HAdV-5 to a degree that prevents independent
isolation. Similar attempts were made with a few samples
that had HAdV-4/HAdV-7 co-infections, but these were
generally biased in titer (104 in favor of HAdV-7) and, as
expected, yielded only HAdV-7 in >300 plaques tested.
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co-infectant (HAdV-7) and physical independence of the
co-infecting entities but could not conclusively demon-
strate functional independence of the minor co-infectant.
Conventional clinical microbiologic methods, includ-
ing microneutralization and hemagglutination inhibition,
are comparative and designed to identify the primary
HAdV serotype (or species) in a sample. Secondary infec-
tions are masked in these methods by the tests (e.g.,
microneutralization is reported as the strongest reaction,
not the spectrum of reactions across all serotypes).
Likewise, direct sequencing (16) may restrict identifica-
tion to a single strain, particularly if 1 co-infectant is dom-
inant. Restriction enzyme analysis methods are capable of
resolving HAdV-C dual infections in which both serotypes
are present in similar numbers (27). In contrast, when
using sensitive molecular methods that can yield measura-
ble signals from secondary (less numerous) co-infectants
against the background of stronger signals produced by
primary infecting strains, these methods may identify co-
infections more than do conventional methods. In the case
of respiratory infections, this finding has previously been
documented (41). 
Finally, each of the methods designed to test for multi-
ple species or serotypes showed a higher number of HAdV
(and accepted virulent HAdV species and serotypes) in
vaccinated persons than in unvaccinated persons. HAdV
vaccine was administered routinely to all trainees until
supplies were exhausted, at which point adenovirus vacci-
nation was stopped. Since trainees were vaccinated sys-
tematically, persons tended to be sampled at times when
either all or no recruits were being vaccinated. Therefore,
vaccinated samples collected and tested (from 1996 to
1998) are not concurrent with unvaccinated samples (col-
lected from 1998 to 2000). Because of this sampling limi-
tation, we could not confidently correlate HAdV
co-infection with breakthrough infections in previously
vaccinated persons. Thus, although this study highlights
the previously underappreciated phenomenon of adenovi-
ral co-infection, the conclusive examination of its relation-
ship to vaccination must await reintroduction of HAdV
vaccine (15).
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